[go: up one dir, main page]

AR096865A1 - Proceso para la preparación de un intermediario de pirimidina - Google Patents

Proceso para la preparación de un intermediario de pirimidina

Info

Publication number
AR096865A1
AR096865A1 ARP140102549A ARP140102549A AR096865A1 AR 096865 A1 AR096865 A1 AR 096865A1 AR P140102549 A ARP140102549 A AR P140102549A AR P140102549 A ARP140102549 A AR P140102549A AR 096865 A1 AR096865 A1 AR 096865A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
pyrimidine
intermediary
Prior art date
Application number
ARP140102549A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR096865A1 publication Critical patent/AR096865A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Detergent Compositions (AREA)
  • Magnetic Heads (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Cores, Coils, And Magnets (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un proceso para la elaboración del compuesto de la fórmula (1) donde dicho proceso comprende la reacción del compuesto de la fórmula (2) donde G¹ representa halógeno, o una sal de dicho compuesto, con etilenglicol en presencia de una base, caracterizado porque, luego de obtener el compuesto de la fórmula (1), se realiza una extracción de líquido-líquido, donde se usa metil iso-butil cetona para extraer el compuesto de la fórmula (1) de una fase acuosa que contiene los productos de la reacción del compuesto de la fórmula (2) con etilenglicol.
ARP140102549A 2013-07-12 2014-07-10 Proceso para la preparación de un intermediario de pirimidina AR096865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13176374 2013-07-12

Publications (1)

Publication Number Publication Date
AR096865A1 true AR096865A1 (es) 2016-02-03

Family

ID=48790244

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102549A AR096865A1 (es) 2013-07-12 2014-07-10 Proceso para la preparación de un intermediario de pirimidina

Country Status (17)

Country Link
US (1) US9556125B2 (es)
EP (1) EP3019479B1 (es)
JP (1) JP6375374B2 (es)
KR (1) KR102305298B1 (es)
CN (1) CN105636940B (es)
AR (1) AR096865A1 (es)
CA (1) CA2915736C (es)
DK (1) DK3019479T3 (es)
ES (1) ES2636937T3 (es)
HR (1) HRP20171166T1 (es)
HU (1) HUE034071T2 (es)
IL (1) IL243477B (es)
MX (1) MX360768B (es)
PL (1) PL3019479T3 (es)
PT (1) PT3019479T (es)
TW (1) TWI643848B (es)
WO (1) WO2015004265A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201605808B (en) 2015-08-26 2017-08-30 Cipla Ltd Process for preparing an endothelin receptor antagonist
CN105461638A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种马西替坦晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323079T1 (de) * 2000-12-18 2006-04-15 Actelion Pharmaceuticals Ltd Neue sulfamiden und deren verwendung als endothelin-antagonisten
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法

Also Published As

Publication number Publication date
MX360768B (es) 2018-11-15
TWI643848B (zh) 2018-12-11
EP3019479A1 (en) 2016-05-18
KR102305298B1 (ko) 2021-09-27
HUE034071T2 (en) 2018-01-29
JP2016525094A (ja) 2016-08-22
KR20160030972A (ko) 2016-03-21
US9556125B2 (en) 2017-01-31
CA2915736C (en) 2021-07-27
CA2915736A1 (en) 2015-01-15
JP6375374B2 (ja) 2018-08-15
PT3019479T (pt) 2017-08-11
DK3019479T3 (en) 2017-07-17
TW201536759A (zh) 2015-10-01
HRP20171166T1 (hr) 2017-10-06
CN105636940A (zh) 2016-06-01
US20160145215A1 (en) 2016-05-26
PL3019479T3 (pl) 2017-10-31
CN105636940B (zh) 2018-02-27
ES2636937T3 (es) 2017-10-10
EP3019479B1 (en) 2017-05-10
WO2015004265A1 (en) 2015-01-15
MX2016000386A (es) 2016-04-29
IL243477B (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CL2016001366A1 (es) Presentación de antígeno de cáncer mejorado a células que presentan antígeno por la descomposición eléctrica de membrana por radiofrecuencia (rf-emb) como un mecanismo adyuvante para la inmunoterapia.
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
MX385720B (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112017023522A2 (pt) processo para a cetonização descarboxilativa de ácidos graxos, derivados de ácido graxo ou misturas dos mesmos
MX377942B (es) Proceso para la preparacion de oxiranos y triazoles.
AR095727A1 (es) Preparación de intermediarios de pirimidina
MX387483B (es) Preparación farmacéutica.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
IL247501B (en) Process for producing a stable low concentration, injectable solution of noradrenaline
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CL2016002546A1 (es) Método para procesar una corriente hemicelulósica acuosa con un alcohol alquílico a temperatura elevada y ph ácido y separar la mezcla obtenida.
CY1119888T1 (el) Μεθοδος για την παρασκευη ξανθοχουμολης
AR095211A1 (es) Utilización de compuestos con funciones amida y fosfonato para extraer el uranio (vi) de soluciones acuosas de ácido sulfúrico, resultantes en particular de la lixiviación sulfúrica de minerales uraníferos y procedimiento de recuperación de uranio
MX2017006200A (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
MX2016009125A (es) Proceso para la sintesis mejorada de oximorfona.
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2015015151A (es) Metodo para producir 4-hidroxi-4-metil-tetrahidropiranos 2-sustituidos, donde dicho proceso usa reciclado.
BR112019001366A2 (pt) catalisadores para a produção de ácido acrílico a partir de ácido lático ou seus derivados em fase líquida
BR112015004793A2 (pt) aparelho e método energeticamente eficientes para a extração de biomoléculas de solução aquosa diluída
BR112017009465A2 (pt) processos para recuperar álcoois
AR096865A1 (es) Proceso para la preparación de un intermediario de pirimidina
EA201990093A1 (ru) Двухкомпонентная композиция
MX2016007117A (es) Barra de jabon.

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FG Grant, registration